switching from semaglutide to tirzepatide for weight loss Experiences switching from semaglutide to

dose-dependent GI adverse events (nausea, vomiting) similar to other amylin analogues Exposure: Dose-proportional increases in Cmax and AUC Gastric Effects: Dose-dependent slowing of gastric emptying confirmed via paracetamol absorption test Appetite Suppression: Reduced ad libitum food intake at doses 1.2 mg Clinical Significance: Established feasibility of once-weekly dosing and identified dose range for Phase 2 studies

[29, 30, 31] Risk factors: Diabetes (especially in combination with SGLT2 inhibitors use) Reduced oral intake and severe GI symptoms Dehydration Presentation: Nausea, vomiting, abdominal pain Anion gap metabolic acidosis Elevated ketones Normal or mildly elevated glucose Key point: EDKA has not been observed in non-diabetic patients in large cohort data

Vitamin C works best when you use it correctly

For some individuals, particularly women approaching or in perimenopause, this shift can unmask or worsen androgenic alopecia, a pattern of hair thinning driven by dihydrotestosterone (DHT) sensitivity in genetically predisposed follicles

It is conceivable that the calcium pulses may be initiated as a result of a spike train resulting from voltagedependent conductance